Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

Adopt a moratorium on heritable genome editing

Eric Lander, Françoise Baylis, Feng Zhang, Emmanuelle Charpentier, Paul Berg and specialists from seven countries call for an international governance framework.
  1. Eric S. Lander

    1. Eric S. Lander is president and founding director of the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Françoise Baylis

    1. Françoise Baylis is a university research professor, Dalhousie University, Halifax, Canada.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Feng Zhang

    1. Feng Zhang is a core member of the Broad Institute of MIT and Harvard.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Emmanuelle Charpentier

    1. Emmanuelle Charpentier is founding and acting head of the Max Planck Unit for the Science of Pathogens in Berlin, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. Paul Berg

    1. Paul Berg is Robert W. and Vivian K. Cahill Emeritus Professor in the biochemistry department at Stanford University, Stanford, California, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  6. Catherine Bourgain

    1. Catherine Bourgain is head of the Center for Research in Medicine, Science, Health, Mental Health, and Society at the University of Paris Descartes, Paris, France.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  7. Bärbel Friedrich

    1. Bärbel Friedrich is professor emeritus, Faculty of Biology, Humboldt University Berlin, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  8. J. Keith Joung

    1. J. Keith Joung is professor of pathology at Harvard Medical School, Boston, Massachusetts.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  9. Jinsong Li

    1. Jinsong Li is a professor at Shanghai Institute of Biochemistry and Cell Biology, Shanghai, China.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  10. David Liu

    1. David Liu is Richard Merkin Professor and director of the Merkin Institute of Transformative Technologies in Healthcare at the Broad Institute of MIT and Harvard.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  11. Luigi Naldini

    1. Luigi Naldini is director of the San Raffaele Telethon Institute for Gene Therapy, Università Vita-Salute San Raffaele, Italy.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  12. Jing-Bao Nie

    1. Jing-Bao Nie is a professor at the Bioethics Centre/Te Pokapū Matatika Koiora, University of Otago/Te Whare Wānanga o Otāgo.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  13. Renzong Qiu

    1. Renzong Qiu is professor emeritus at the Institute of Philosophy, Chinese Academy of Social Sciences & Center for Bioethics, Huazhong University of Science and Technology, Wuhan, China.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  14. Bettina Schoene-Seifert

    1. Bettina Schoene-Seifert is chair for medical ethics, University of Münster, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  15. Feng Shao

    1. Feng Shao is professor and deputy director, National Institute of Biological Sciences (NIBS), Beijing, China.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  16. Sharon Terry

    1. Sharon Terry is president and chief executive of Genetic Alliance, Washington DC, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  17. Wensheng Wei

    1. Wensheng Wei is a professor at Peking University College of Life Sciences, Beijing, China.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  18. Ernst-Ludwig Winnacker

    1. Ernst-Ludwig Winnacker is professor-emeritus at Gene Center Munich, Department of Biochemistry, University of Munich, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

We call for a global moratorium on all clinical uses of human germline editing — that is, changing heritable DNA (in sperm, eggs or embryos) to make genetically modified children.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 567, 165-168 (2019)

doi: https://doi.org/10.1038/d41586-019-00726-5

References

  1. Araki, M. & Ishii, T. Reprod. Biol. Endocrinol. 12, 108 (2014).

    Article  PubMed  Google Scholar 

  2. Pontin, J. ‘The Genetics (and Ethics) of Making Humans Fit for Mars’ Wired (8 July 2018).

  3. Regalado, A. ‘The DIY designer baby project funded with Bitcoin’ MIT Technol. Rev. (1 February 2019).

  4. Hurlbut, J. B. Nature 565, 135 (2019).

    Article  PubMed  Google Scholar 

  5. National Academies of Sciences, Engineering, and Medicine. Human Genome Editing: Science, Ethics, and Governance (National Academies Press, 2017).

    Google Scholar 

  6. Costas, J. Am. J. Med. Genet. B Neuropsychiatr. Genet. 177, 274–283 (2018).

    Article  PubMed  Google Scholar 

  7. Joy, M. T. et al. Cell 176, 1143–1157 (2019).

    Article  PubMed  Google Scholar 

  8. Steffann, J., Jouannet, P., Bonnefont, J. P., Chneiweiss, H. & Frydman, N. Cell Stem Cell 22, 481–482 (2018).

    Article  PubMed  Google Scholar 

  9. Jasanoff, S. & Hurlbut, J. B. Nature 555, 435–437 (2018).

    Article  PubMed  Google Scholar 

  10. Langlois, A. Palgrave Commun. 3, 17019 (2017).

    Article  PubMed  Google Scholar 

  11. Burall, S. Nature 555, 438–439 (2018).

    Article  PubMed  Google Scholar 

  12. Baylis, F. Nature Hum. Behav. 1, 0103 (2017).

    Article  Google Scholar 

  13. Hurlbut, J. B. et al. Trends Biotechnol. 36, 639–641 (2018).

    Article  PubMed  Google Scholar 

  14. Saha, K. et al. Trends Biotechnol. 36, 741–743 (2018).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

Eric Lander (E.L.) notes that institutions with which he is associated — Broad Institute, MIT and Harvard — have interests in CRISPR technology, including patents and patent applications, and that he is a co-inventor on certain patents and patent applications relating to CRISPR-based gene-editing technologies. He also serves on the board of directors for Codiak BioSciences and Neon Therapeutics, and serves on the scientific advisory board of F-Prime Capital Partners and Third Rock Ventures. Feng Zhang (F.Z.) is a founder and scientific adviser for Editas Medicine, Beam Therapeutics, Arbor Biotechnologies, and Pairwise Plants. F.Z. is also an inventor on a number of issued patents and applications relating to CRISPR-based gene-editing technologies. Emmanuelle Charpentier (E.C.) is a co-founder of CRISPR Therapeutics and ERS Genomics and is a member of the scientific advisory board of CRISPR Therapeutics. J. Keith Joung (J.K.J.) has financial interests in Beam Therapeutics, Editas Medicine, Endcadia, EpiLogic Therapeutics, Pairwise Plants, Poseida Therapeutics, and Transposagen Biopharmaceuticals. J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. J.K.J. is a member of the board of directors of the American Society of Gene and Cell Therapy. J.K.J. is a co-inventor on various patents and patent applications that describe gene-editing technologies. David R. Liu (D.R.L.) is a consultant and co-founder of Beam Therapeutics, Editas Medicine, and Pairwise Plants, companies that use genome editing, and is a co-inventor on genome editing patents. Complete financial disclosures are available at https://liugroup.us/david-r-liu/. Wensheng Wei (W.W.) serves as a scientific adviser for EdiGene.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links